Treatment of cancer of the exocrine pancreas

American Journal of Surgery

Volumn 177, Issue 3, 1999, Pages 257-265

  Huguier, Michel ^a   Mason, Nicholas P ^b  

^a Service de Chirurgie Digestive   (France)

^b HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOSINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; MITOMYCIN; STREPTOZOCIN;

ADJUVANT CHEMOTHERAPY; ARTICLE; BILE DUCT OBSTRUCTION; CANCER CHEMOTHERAPY; HORMONAL THERAPY; INCIDENCE; PALLIATIVE THERAPY; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 0032937302     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(99)00003-3     Document Type: Review

References (99)

1. Bakkevold K.E., Kambestad B. Morbidity and mortality after radical and palliative pancreatic cancer surgery. Ann Surg. 217:1993;356-368.
2. Huguier M., Baumel H., Manderscheid J.C., et al. Surgical palliation for unresected cancer of the exocrine pancreas. Eur J Clin Oncol. 19:1993;342-347.
3. Baumel H., Huguier M., Manderscheid J.C., et al. Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery. Br J Surg. 81:1994;102-107.
4. Fong Y., Blumgart L.H., Fortner J.G., et al. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg. 222:1995;426-437.
5. Vickers S.M., Kerby J.D., Smoot T.M., et al. Economics of pancreatoduodenectomy in the elderly. Surgery. 120:1996;620-626.
6. Prêtre R., Huber O., Robert J., et al. Results of surgical palliation for cancer of the head of the pancreas and periampullary region. Br J Surg. 79:1992;795-798.
7. John T.G., Greig J.D., Carter D.C., et al. Carcinoma of the pancreatic head and periampullary region. Tumor staging with laparoscopy and laparoscopic ultrasonography. Ann Surg. 221:1995;156-164.
8. Conlon K.V., Dougherty E., Klimstra D.S., et al. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg. 223:1996;134-140.
9. Bornman P.C., Harries-Jones E.P., Tobias R., et al. Prospective controlled trial of transhepatic biliary endoprothesis versus bypass surgery for incurable carcinoma of head of pancreas. Lancet. 1:1986;69-71.
10. Sheperd H.A., Royle G., Ross A.P.R., et al. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct a randomized trial . Br J Surg. 75:1988;1166-1168.
11. Andersen J.R., Sorensen S.M., Kruse A., et al. Randomized trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut. 30:1989;1132-1135.
12. Smith A.C., Dowsett J.F., Russell R.C.G., et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet. 344:1994;1655-1660.
13. Van den Bosch R.P., van der Schelling G.P., Klinlenbijl J.H., et al. Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas. Ann Surg. 219:1994;18-24.
14. Geer R.J., Brennan M.F. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 163:1993;68-72.
15. Bramhall S.R., Allum W.H., Jones A.G., et al. Treatment and survival in 13 560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands an epidemiological study . Br J Surg. 82:1995;111-115.
16. Niederhuber J.E., Brennan M.F., Menck H.R. The National Cancer Data base report on pancreatic cancer. Cancer. 76:1995;1671-1677.
17. Conlon K.C., Klimstra D.S., Brennan M.F. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 223:1996;273-279.
18. Delcore R., Rodriguez F.J., Forster J., et al. Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am J Surg. 172:1996;463-468.
19. Huguier M., Baumel H., Manderscheid J.C.H. Cancer of the exocrine pancreas. A plea for resection. Hepatogastroenterology. 43:1996;721-729.
20. Sperti C., Pasquali C., Piccoli A., et al. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg. 83:1996;625-631.
21. Klinkenbijl J.H.G., Jeekel J., Schmitz P.I.M., et al. Carcinoma of the pancreas and periampullary region palliation versus cure . Br J Surg. 80:1993;1575-1578.
22. Lillemoe K.D., Cameron J.L., Yeo C.J., et al. Pancreatoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg. 223:1996;718-728.
23. Potts J.R., Broughan T.A., Hermann R.E. Palliative operation for pancreatic carcinoma. Am J Surg. 159:1990;72-77.
24. Sarfeh I.J., Rypins E.B., Jakowatz J.G., et al. A prospective randomized clinical investigation of cholecystoenterostomy and choledocoenterostomy. Am J Surg. 155:1988;411-414.
25. Neuburger T.J., Wade T.P., Swope T.J., et al. Palliative operations for pancreatic cancer in the hospitals of the U.S. Department of Veterans affairs from 1987 to 1991. Am J Surg. 166:1993;632-636.
26. Doberneck R.C., Berndt G.A. Delayed gastric emptying after palliative gastrojejunostomy for carcinoma of the pancreas. Arch Surg. 122:1987;827-829.
27. Lillemoe K.D., Cameron J.L., Kaufman H.S., et al. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. Ann Surg. 217:1993;447-457.
28. Singh S.M., Longmire W.P., Reber H.A. Surgical palliation for pancreatic cancer. The UCLA experience. Ann Surg. 212:1990;132-139.
29. Gordon T.A., Burleyson G.P., Tielsch J.M., et al. The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg. 221:1995;43-49.
30. Lieberman M.D., Jilburn H., Lindsey M., et al. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg. 222:1995;638-645.
31. Janes R.H., Niederhuber J.E., Chmiel J.S., et al. National patterns of care for pancreatic cancer. Results of a survey by the Commission of Cancer. Ann Surg. 223:1996;261-272.
32. Neoptolemos J.P., Russell R.C.G., Bramhall S., et al. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients UK survey of specialist pancreatic units . Br J Surg. 84:1997;1370-1376.
33. Fortner J.G., Klimstra D.S., Senie R.T., et al. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg. 223:1996;147-153.
34. Wade T.P., Halaby I.A., Stapleton D.R., et al. Population-based analysis of treatment of pancreatic cancer and Whipple resection Department of Defense hospitals, 1989-1994 . Surgery. 120:1996;680-687.
35. Trede M., Schwall G., Saeger H.D. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg. 211:1990;447-458.
36. Fernandez-del Castillo C., Rattner D., Warshaw A.L. Standards for pancreatic resection in the 1990s. Arch Surg. 130:1995;295-300.
37. Klempnauer J., Ridder G.J., Pichlmayr R. Prognostic factors after resection of ampullary carcinoma multivariate survival analysis in comparison with ductal cancer of pancreatic head . Br J Surg. 82:1995;1686-1691.
38. Yeo C.J., Abrams R.A., Grochow L.B., et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective single institution experience. Ann Surg. 225:1997;621-633.
39. Mediema B.W., Sarr M.G., van Heerden J.A., et al. Complications following pancreaticoduodenectomy. Current management. Arch Surg. 127:1992;945-950.
40. Büchler M., Friess H., Klempa I., et al. Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg. 163:1992;125-130.
41. Montorsi M., Zago M., Mosca F., et al. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections a prospective, controlled, randomized clinical trial . Surgery. 117:1995;26-31.
42. Marcus S.G., Cohen H., Ranson J.H. Optimal management of the pancreatic remnant after pancreaticoduodenectomy. Ann Surg. 221:1995;635-648.
43. Lowy A.M., Lee J.E., Pisters P.W.T., et al. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg. 226:1997;632-641.
44. Delcore R., Thomas J.H., Pierce G.E., et al. Pancreatogastrostomy a safe drainage procedure after pancreatoduodenectomy . Surgery. 108:1990;641-647.
45. Mason G.R., Freeark R.J. Current experience with pancreaticogastrostomy. Am J Surg. 169:1995;217-219.
46. Yeo C.J., Cameron J.L., Maher M.M., et al. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg. 222:1995;580-592.
47. Yeo C.J., Barry M.K., Sauter P.K., et al. Erythromycin accelerates gastric emptying after pancreaticoduodenectomy. A prospective, randomized, placebo-controlled trial. Ann Surg. 218:1993;229-238.
48. Klinkenbijl J.H.G., van der Schelling G.P., Hop W.C.J., et al. The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region. Ann Surg. 216:1992;142-145.
49. Roder J.D., Stein H.J., Hüttl W., et al. Pylorus-preserving versus standard pancreatico-duodenectomy an analysis of 110 pancreatic and periampullary carcinomas . Br J Surg. 79:1992;152-155.
50. Zerbi A., Balzano G., Patuzzo R., et al. Comparison between pylorus-preserving and Whipple pancreatoduodenectomy. Br J Surg. 82:1995;975-979.
51. Patel A.G., Toyama M.T., Kusske A.M., et al. Pylorus-preserving Whipple resection for pancreatic cancer. Is it any better? Arch Surg. 130:1995;838-842.
52. Nakao A., Harada A., Nonami T., et al. Lymph node metastases in carcinoma of the head of the pancreas region. Br J Surg. 82:1995;399-402.
53. Tsao JI, Rossi RI, Lowell JA. Pylorus-preserving pancreatoduodenectomy. Is it an adequate cancer operation? Arch Surg. 1994;129:405-12.5.
54. Brooks J.R., Brooks D.C., Levine J.D. Total pancreatectomy for ductal cell carcinoma of the pancreas. An update. Ann Surg. 209:1989;405-410.
55. Launois B., Franci J., Bardaxoglou E., et al. Total pancreatectomy for ductal adenocarcinoma of the pancreas with special reference to resection of the portal vein and multicentric cancer. World J Surg. 17:1993;122-127.
56. Desler C.M., Fortner J.G., McDermott K., et al. Metabolic consequences of (regional) total pancreatectomy. Ann Surg. 214:1991;131-140.
57. Swope T.J., Wade T.P., Neuberger T.J., et al. A reappraisal of total pancreatectomy for pancreatic cancer: results from U.S. Veterans Affairs Hospitals, 1987-1991. Am J Surg. 168:1994;582-585.
58. Permert J., Ihse I., Jorfeldt L., et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg. 80:1993;1047-1050.
59. Tashiro S., Uchino R., Hiraoka T., et al. Surgical indication and significance of portal vein resection in biliary and pancreatic cancer. Surgery. 109:1991;481-487.
60. Nakao A., Harada A., Nonami T., et al. Clinical significance of portal invasion by pancreatic head carcinoma. Surgery. 117:1995;50-55.
61. Fuhrman G.M., Leach S.D., Staley C.A., et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Ann Surg. 223:1996;154-162.
62. Harrison L.E., Klimstra D.S., Brennan M.F. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg. 224:1996;342-349.
63. Roder J.D., Stein H.J., Siewert J.R. Carcinoma of the periampullary region who benefits from portal vein resection? Am J Surg. 171:1996;170-175.
64. Ishikawa O., Ohigashi H., Imaoka S., et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg. 215:1992;231-236.
65. Ishikawa O., Ohigashi H., Sasaki Y., et al. Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy. Surgery. 121:1997;244-249.
66. LaValle G., Martinez D.A., Sobel D., et al. Assessment of disseminated pancreatic cancer a comparison of traditional exploratory laparotomy and radioimmunoguided surgery . Surgery. 122:1997;867-873.
67. Fabre J.M., Houry S., Mandescheid J.C., et al. Surgery of left-sided pancreatic cancer. Br J Surg. 83:1996;1065-1070.
68. Dalton R.R., Sarr M.G., van Heerden J.A., et al. Carcinoma of the body and tail of the pancreas is curative resection justified? Surgery. 111:1992;489-494.
69. Nordback I.H., Hruban R.H., Boitnott J.K., et al. Carcinoma of the body and tail of the pancreas. Am J Surg. 164:1992;26-31.
70. Brennan M.F., Moccia R.D., Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg. 223:1996;506-512.
71. Nakao A., Harada A., Nonami T., et al. Lymph node metastasis in carcinoma of the body and tail of the pancreas. Br J Surg. 84:1997;1090-1092.
72. Cullinan S., Moertel C.G., Wieand H.S., et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluation of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer. 65:1990;2207-2212.
73. Tophan C., Glees J., Rawson N.S.B., et al. Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas. Br J Cancer. 64:1991;179-181.
74. Kelsen D., Hudis C., Niedzwiecki D., et al. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 68:1991;965-969.
75. Palmer K.P., Kerr M., Knowles G., et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg. 81:1994;882-885.
76. Glimelius B., Hoffman K., Sjödén P.O., et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 7:1996;593-600.
77. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer a randomized trial . J Clin Oncol. 15:1997;2403-2413.
78. Bakkevold K.E., Arnesjo B., Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater. Results of a controlled, prospective, randomised multicentre study. Eur J Cancer. 29A:1993;698-703.
79. Klaassen D.J., MacIntyre J.M., Catton G.E., et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil. An Eastern cooperative oncology group study. J Clin Oncol. 3:1985;373-378.
80. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer. 56:1985;2563-2568.
81. Earle J.D., Foley J.F., Wieand H.S., et al. Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthome (HYC) in confined, unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 28:1994;207-211.
82. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 59:1987;2006-2010.
83. Dobelbower R.R., Konski A.A., Merrick H.W., et al. Intraoperative electron therapy (IOEBRT) for carcinoma of the exocrine pancreas. Int J Radiat Oncol Biol Phys. 20:1991;113-119.
84. Kasperk R., Klever P., Andreopoulos D., et al. Intraoperative radiotherapy for pancreatic carcinoma. Br J Surg. 82:1995;1259-1261.
85. Sindelar W.F., Kinsella T.J., Tepper J., et al. National Cancer Institute randomized trial of intraoperative radiotherapy in unresectable pancreatic cancer. Hepato-Gastroenterology. 41:1994;S2. Abstract.
86. Evans D.B., Termuhlen P.M., Byrd D.R., et al. Intraoperative radiation therapy following pancreaticoduodenectomy. Ann Surg. 218:1993;54-60.
87. Sindelar W.F., Kinsella T.J., Tepper J., et al. National Cancer randomized trial of intraoperative radiotherapy in resectable pancreatic cancer. Hepato-Gastroenterology. 41:1994;S2. Abstract.
88. Zerbi A., Fossati V., Parolini D., et al. Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer. Cancer. 73:1994;2930-2935.
89. Staley C.A., Lee J.E., Cleary K.R., et al. Preoperative chemoradiation, pancreatoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg. 171:1996;118-125.
90. Huguier M., Samama G., Testart J., et al. From the French Association for Surgical Research: treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). Am J Surg. 164:1992;348-353.
91. Keating J.J., Johnson P.J., Cochrane A.M.G., et al. A prospective randomised controlled trial of tamoxifen and cyproteron acetate in pancreatic carcinoma. Br J Cancer. 60:1989;789-792.
92. Bakkevold K.E., Pettersen A., Arnesjo B., et al. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg. 77:1990;725-730.
93. Taylor O.M., Benson E.A., McMahon M.J., et al. Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. Br J Surg. 80:1993;384-386.
94. Jessup J.M., Steele G., Mayer R.J., et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg. 128:1993;559-563.
95. Aigner K.R., Müller H., Bassermann R. Intra-arterial chemotherapy with MMC, CDDP and 5-FU for nonresectable pancreatic cancer: a phase II study. Reg Cancer Treat. 3:1990;1-6.
96. Evrard S., Keller P., Hajri A., et al. Experimental pancreatic cancer in the rat treated by photodynamic therapy. Br J Surg. 81:1994;1185-1189.
97. Cameron J.L., Crist D.W., Sitzmann J.V., et al. Factors influencing survival after pancreticoduodenectomy for pancreatic cancer. Am J Surg. 161:1991;120-125.
98. Allema J.H., Reinders M.E., van Gulik T.M., et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer. 75:1995;2069-2076.
99. Brennan M.F., Pisters P.W.T., Posner M., et al. A prospective randomized trial of total parenteral nutrition after major pancreatic resection for malignancy. Ann Surg. 220:1994;436-444.